La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
Fibroblast Activation Protein: an emerging high-value theranostic target for delivery of payloads STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis. Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers,...
Glypican-3 (GPC3): an emerging liver cancer target with opportunities for different effector mechanisms STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis. GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma...
B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis. B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in...
The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic...
BARCELONA, Spain I May 13, 2022 I La Merie Publishing released today its newest report entitled “Claudin 6: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Claudin 6 (CLDN6)...
BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...
BARCELONA, Spain I March 07, 2022 I La Merie Publishing announced today the launch of the 2nd edition of its report about targeted protein degradation. The report “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing” describes and...
BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective” provides a landscape description and...
BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an...
BARCELONA, Spain I May 14, 2020 I La Merie Publishing announced the release of its newest report about Targeted Protein Degradation. The report “Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective” provides a landscape...
